10Jul
Proactive Due Diligence Considerations for Life Sciences Dealmakers
In today’s competitive and fast-paced life sciences dealmaking environment, buyers and investors are often unable to spend as much time on due diligence as they might like. Market players are often highly focused on the science itself and, as a...
By:
McDermott Will & Emery
Related
In anticipation of its November Board meeting this past week, the Medical Board released its Medical...
Read More >
The Ninth Circuit signaled that it might rehear Dorman v. The Charles Schwab Corp., where earlier th...
Read More >
Introduction and Background - On January 29, 2020, the Second Department affirmed a Suffolk County ...
Read More >
For the first time in over 60 years, the U.S. Department of Labor today issued a final rule updating...
Read More >
2020 AG Elections -Republican John Westercamp Announces Candidacy for Indiana Attorney General -Jo...
Read More >
Healthcare businesses represent essential transaction opportunities in the middle market. Despite th...
Read More >